Amicus Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:FOLD

Comments

Amicus Therapeutics Inc Earnings Estimates

FOLDNASDAQ

Trade with Public

$14.34

0.010.07%

At close: Mar 6, 4:00 PM EST

$14.40

0.060.42%

After Hours: Mar 6, 5:12 PM EST

Overview NewsEarningsOptions Guidance Analyst Ratings Insider Trades Short Interest Government Trades Stock Report

Amicus Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:FOLD

Amicus Therapeutics (FOLD) is scheduled to report Q1 earnings on April 30, 2026. Analysts estimate EPS of $0.08 and quarterly revenue of $164.56M.

In the most recent quarter (Q4), Amicus Therapeutics reported EPS of $0.10, missing estimates of $0.14 by 0.29%. Revenue came in at $185.21M, exceeding the estimate of $182.96M by 0.01%.

Over the last 4 quarters, Amicus Therapeutics has averaged an EPS surprise of 0.95% and a revenue surprise of 0.04%.

Earnings Date

Apr 30

EPS Estimate

$0.080

Quarterly Revenue Estimate

$164.56M

Annual Revenue
(as of Sep 30)

$598.70M

Amicus Therapeutics Earnings History

Analyze the earnings history of Amicus Therapeutics using advanced sorting and filters.

Amicus Therapeutics (FOLD) Earnings Per Share

The chart below shows Amicus Therapeutics's reported EPS compared to analyst estimates over recent quarters.

Amicus Therapeutics (FOLD) Revenue

The chart below shows Amicus Therapeutics's reported revenue compared to analyst estimates over recent quarters.

FAQ

When is Amicus Therapeutics (NASDAQ:FOLD) reporting earnings?

Amicus Therapeutics (FOLD) is scheduled to report earnings on April 30, 2026. The last reported earnings were for reported on February 20, 2026 for Q4.

What were the latest earnings per share (EPS) for Amicus Therapeutics (NASDAQ:FOLD)?

The Actual EPS was $0.10, which missed the estimate of $0.14.

What were Amicus Therapeutics’s (NASDAQ:FOLD) revenues?

The Actual Revenue was $185.21M, which beat the estimate of $182.96M.

People Also Watch

Twist Bioscience Corp

Centessa Pharmaceuticals PLC

NASDAQ:CNTA

$25.95

Arcutis Biotherapeutics Inc

NASDAQ:ARQT

$23.69

-1.29%

Xenon Pharmaceuticals Inc

Amicus Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:FOLD

Amicus Therapeutics (FOLD) is scheduled to report Q1 earnings on April 30, 2026. Analysts estimate EPS of $0.08 and quarterly revenue of $164.56M.

In the most recent quarter (Q4), Amicus Therapeutics reported EPS of $0.10, missing estimates of $0.14 by 0.29%. Revenue came in at $185.21M, exceeding the estimate of $182.96M by 0.01%.

Over the last 4 quarters, Amicus Therapeutics has averaged an EPS surprise of 0.95% and a revenue surprise of 0.04%.

Earnings Date

Apr 30

EPS Estimate

$0.080

Quarterly Revenue Estimate

$164.56M

Annual Revenue
(as of Sep 30)

$598.70M